Kaitlin J. Mayne

1.5k total citations
23 papers, 125 citations indexed

About

Kaitlin J. Mayne is a scholar working on Nephrology, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Kaitlin J. Mayne has authored 23 papers receiving a total of 125 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Nephrology, 6 papers in Surgery and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Kaitlin J. Mayne's work include Dialysis and Renal Disease Management (8 papers), Chronic Kidney Disease and Diabetes (6 papers) and Diabetes Treatment and Management (6 papers). Kaitlin J. Mayne is often cited by papers focused on Dialysis and Renal Disease Management (8 papers), Chronic Kidney Disease and Diabetes (6 papers) and Diabetes Treatment and Management (6 papers). Kaitlin J. Mayne collaborates with scholars based in United Kingdom, Germany and Australia. Kaitlin J. Mayne's co-authors include Jennifer S. Lees, Patrick B. Mark, William G. Herrington, Michael Sullivan, Jean-Marc Extra, David Robert Grimes, Claudio Ronco, F. Cognetti, Shiu‐Wan Chan and David Keane and has published in prestigious journals such as Journal of the American Society of Nephrology, European Journal of Cancer and Clinical Journal of the American Society of Nephrology.

In The Last Decade

Kaitlin J. Mayne

19 papers receiving 124 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kaitlin J. Mayne United Kingdom 6 47 38 22 19 18 23 125
Yasin Yüksel Türkiye 7 44 0.9× 22 0.6× 15 0.7× 19 1.0× 62 3.4× 20 126
Adrian Tulin Romania 7 23 0.5× 23 0.6× 7 0.3× 53 2.8× 20 1.1× 37 202
María Fernanda Slon Roblero Spain 4 7 0.1× 51 1.3× 52 2.4× 14 0.7× 15 0.8× 9 137
T. B. Pecherina Russia 7 12 0.3× 10 0.3× 12 0.5× 30 1.6× 75 4.2× 29 127
Johanna Inhestern Germany 9 82 1.7× 17 0.4× 18 0.8× 104 5.5× 6 0.3× 14 258
Ying Kuan United Kingdom 4 7 0.1× 47 1.2× 6 0.3× 10 0.5× 11 0.6× 7 119
Kuan‐Chieh Fang Taiwan 7 33 0.7× 4 0.1× 7 0.3× 39 2.1× 17 0.9× 10 296
Jennifer Pascoe United Kingdom 6 27 0.6× 10 0.3× 4 0.2× 12 0.6× 14 0.8× 12 94
Satish Shah United States 7 31 0.7× 12 0.3× 3 0.1× 25 1.3× 6 0.3× 19 172
Xi Zhu China 5 15 0.3× 57 1.5× 9 0.4× 16 0.8× 18 1.0× 8 124

Countries citing papers authored by Kaitlin J. Mayne

Since Specialization
Citations

This map shows the geographic impact of Kaitlin J. Mayne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kaitlin J. Mayne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kaitlin J. Mayne more than expected).

Fields of papers citing papers by Kaitlin J. Mayne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kaitlin J. Mayne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kaitlin J. Mayne. The network helps show where Kaitlin J. Mayne may publish in the future.

Co-authorship network of co-authors of Kaitlin J. Mayne

This figure shows the co-authorship network connecting the top 25 collaborators of Kaitlin J. Mayne. A scholar is included among the top collaborators of Kaitlin J. Mayne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kaitlin J. Mayne. Kaitlin J. Mayne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Williams, Claire, Natalie Staplin, Parminder K. Judge, et al.. (2025). Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial. EClinicalMedicine. 85. 103338–103338. 1 indexed citations
2.
Mayne, Kaitlin J., Peter Hanlon, & Jennifer S. Lees. (2024). Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines. Diabetes Obesity and Metabolism. 26(S6). 43–54. 4 indexed citations
3.
Mayne, Kaitlin J., Rebecca J. Sardell, Natalie Staplin, et al.. (2024). Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial. Nephrology Dialysis Transplantation. 40(4). 720–730. 10 indexed citations
4.
Pintér, J, Bernard Canaud, Kaitlin J. Mayne, et al.. (2024). Associations of Abnormal Fluid Status, Plasma Sodium Disorders, and Low Dialysate Sodium with Mortality in Patients on Hemodialysis. Clinical Journal of the American Society of Nephrology. 19(11). 1444–1452. 2 indexed citations
5.
Fletcher, Robert A., William G. Herrington, Rajiv Agarwal, et al.. (2024). Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD. Clinical Journal of the American Society of Nephrology. 19(9). 1180–1182. 1 indexed citations
6.
Nangaku, Masaomi, William G. Herrington, Shinya Goto, et al.. (2024). Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA–KIDNEY. Clinical and Experimental Nephrology. 28(6). 588–595. 1 indexed citations
7.
Pintér, J, Bernard Canaud, Kaitlin J. Mayne, et al.. (2024). #1657 Impact of cumulative fluid and sodium imbalance exposure on cause-specific mortality in hemodialysis. Nephrology Dialysis Transplantation. 39(Supplement_1).
8.
Mayne, Kaitlin J., et al.. (2023). Effects of Empagliflozin on Weight and Blood Pressure in CKD: Analyses from the EMPA-KIDNEY Trial. Journal of the American Society of Nephrology. 34(11S). 678–678. 1 indexed citations
9.
Mayne, Kaitlin J., Michael Sullivan, & Jennifer S. Lees. (2023). Sex and gender differences in the management of chronic kidney disease and hypertension. Journal of Human Hypertension. 37(8). 649–653. 16 indexed citations
10.
Mayne, Kaitlin J. & Claudio Ronco. (2023). Will another trial CONVINCE nephrologists to adopt high-dose haemodiafiltration over conventional haemodialysis?. Clinical Kidney Journal. 16(12). 2393–2395. 5 indexed citations
11.
Mayne, Kaitlin J.. (2023). #4139 EFFECTS OF EMPAGLIFLOZIN ON FLUID OVERLOAD IN CHRONIC KIDNEY DISEASE: AN EMPA-KIDNEY BIOIMPEDANCE SUBSTUDY. Nephrology Dialysis Transplantation. 38(Supplement_1). 1 indexed citations
12.
Mayne, Kaitlin J., et al.. (2022). Bioimpedance Indices of Fluid Overload and Cardiorenal Outcomes in Heart Failure and Chronic Kidney Disease: a Systematic Review. Journal of Cardiac Failure. 28(11). 1628–1641. 18 indexed citations
13.
Mayne, Kaitlin J., Jennifer S. Lees, Elaine Rutherford, et al.. (2022). Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios: associations with mortality in a haemodialysis cohort. Clinical Kidney Journal. 16(3). 512–520. 14 indexed citations
14.
Mayne, Kaitlin J., Jennifer S. Lees, & William G. Herrington. (2022). Bioimpedance in CKD: an untapped resource?. Nephrology Dialysis Transplantation. 38(3). 583–585. 5 indexed citations
15.
Mayne, Kaitlin J., et al.. (2021). An incidental finding of testicular seminoma in the context of acute pulmonary embolism: a case report. Journal of Medical Case Reports. 15(1). 354–354.
16.
Rankin, Alastair J., Kaitlin J. Mayne, Pauline Hall Barrientos, et al.. (2021). Will advances in functional renal magnetic resonance imaging translate to the nephrology clinic?. Nephrology. 27(3). 223–230. 6 indexed citations
17.
Mayne, Kaitlin J., et al.. (2019). Virtual clinics for follow-up of pacemakers and implantable cardioverter defibrillators in children. Cardiology in the Young. 29(10). 1243–1247. 1 indexed citations
18.
Urruticoechea, Ander, Peter Canney, Robert Šeparović, et al.. (2012). 194 A Phase II Study of Trastuzumab Plus Capecitabine with or Without Pertuzumab for HER2-positive Metastatic Breast Cancer as Second-line Treatment (PHEREXA). European Journal of Cancer. 48. S97–S97. 3 indexed citations
19.
Extra, Jean-Marc, F. Cognetti, Shiu‐Wan Chan, et al.. (2003). 672 Randomised phase II trial (M77001) of trastuzumab (Herceptin®) plus docetaxel versus docetaxel alone, as first-line therapy in patients with HER2-positive metastitic breast cancer. European Journal of Cancer Supplements. 1(5). S202–S202. 33 indexed citations
20.
Beale, Philip, Ruth Plummer, Martin Highley, et al.. (1998). Phase I trial of ZD9331 given as a 30 minute infusion on days 1 and 8 with cycles repeated every 3 weeks. UCL Discovery (University College London). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yasin Yüksel Breakdown of academic impact, for papers by Adrian Tulin Breakdown of academic impact, for papers by María Fernanda Slon Roblero Breakdown of academic impact, for papers by T. B. Pecherina Breakdown of academic impact, for papers by Johanna Inhestern Breakdown of academic impact, for papers by Ying Kuan Breakdown of academic impact, for papers by Kuan‐Chieh Fang Breakdown of academic impact, for papers by Jennifer Pascoe Breakdown of academic impact, for papers by Satish Shah Breakdown of academic impact, for papers by Xi Zhu
Rankless by CCL
2026